financetom
Business
financetom
/
Business
/
DoubleVerify's Q2 Results Solid Against Lowered Bar, RBC Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
DoubleVerify's Q2 Results Solid Against Lowered Bar, RBC Says
Jul 31, 2024 10:59 AM

01:35 PM EDT, 07/31/2024 (MT Newswires) -- DoubleVerify Holdings ( DV ) reported solid results for Q2 against a lowered bar as revenue and adjusted EBITDA topped analysts' estimates, RBC Capital Markets said in a note Tuesday.

The company's revenue of $155.9 million and adjusted EBITDA of $46.8 million surpassed the consensus of $153.8 million and $43 million, respectively, RBC said.

"DoubleVerify ( DV ) delivered a solid bounce-back quarter finding stability after consecutive guide downs," RBC said. "While investor confidence will take time to fully rebuild, we like the stability of the quarter."

The firm maintained the company's outperform rating and $33 price target.

Shares of DoubleVerify ( DV ) were down 2.6% in recent Wednesday trading.

Price: 21.03, Change: -0.55, Percent Change: -2.55

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
TG Therapeutics Swings to Q4 Net Income, Revenue Rises; 2025 Revenue Guidance Set
TG Therapeutics Swings to Q4 Net Income, Revenue Rises; 2025 Revenue Guidance Set
Mar 3, 2025
07:24 AM EST, 03/03/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) reported a Q4 net income Monday of $0.15 per diluted share, swinging from loss of $0.10 a year earlier. Analysts polled by FactSet expected earnings of $0.16. Revenue for the quarter ended Dec. 31 was $108.2 million, up from $44 million a year earlier. Analysts surveyed by FactSet...
Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises
Ocular Therapeutix Q4 Net Loss Narrows, Revenue Rises
Mar 3, 2025
07:21 AM EST, 03/03/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) reported Monday a Q4 net loss of $0.29 per diluted share, narrower than its loss of $0.35 per share a year earlier. Analysts polled by FactSet expected a loss of $0.25. Revenue for the quarter ended Dec. 31 was $17.1 million, up from $14.8 million a year earlier....
Orla Mining Completes Acquisition of Musselwhite Gold Mine in Ontario
Orla Mining Completes Acquisition of Musselwhite Gold Mine in Ontario
Mar 3, 2025
07:23 AM EST, 03/03/2025 (MT Newswires) -- Orla Mining ( ORLA ) said Monday that it completed its acquisition of the Musselwhite gold mine in Ontario from Newmont ( NEM ) . Under the terms, the upfront cash consideration of US$810 million consists of debt, gold prepayment, new convertible notes and cash on hand. The company will also pay a...
BioLife Solutions Q4 Loss Narrows, Revenue Rises; 2025 Sales Outlook Set
BioLife Solutions Q4 Loss Narrows, Revenue Rises; 2025 Sales Outlook Set
Mar 3, 2025
07:26 AM EST, 03/03/2025 (MT Newswires) -- BioLife Solutions ( BLFS ) reported a Q4 net loss from continuing operation Monday of $0.04 per diluted share, narrower than a loss of $0.16 a year earlier. Analysts polled by FactSet expected a loss of $0.06. Revenue for the quarter ended Dec. 31 was $22.7 million compared with $17.4 million a year...
Copyright 2023-2026 - www.financetom.com All Rights Reserved